Table 3.
Questionnaires, Diary & Compliance Results
| Hypnotherapy | Pharmacotherapy | P | Estimated Group Difference (95% CI)a | |
|---|---|---|---|---|
| Overactive Bladder questionnaire-Short Form Symptom Botherb Scores | ||||
| Baseline Mean (CI) | 66.88 (61.81–71.94) | 66.99 (62.92–72.07) | 0.97 | −0.11 (−7.23–7.00) |
| 2 months Meansc (CI) | 38.17 (30.19–46.14) | 35.33 (28.64–42.02) | 0.59 | 2.84 (−7.58–13.25) |
| 6 months Meansc (CI) | 34.61 (26.26–42.96) | 27.93 (20.66–35.20) | 0.24 | 6.68 (−4.39–17.76) |
| 12 months Meansc (CI) | 32.27 (22.89–41.66) | 30.74 (22.53–38.95) | 0.81 | 1.53 (−10.94–14.00) |
| Overactive Bladder questionnaire-Short Form Quality of Lifed Scores | ||||
| Baseline Mean (CI) | 47.11 (40.58–53.65) | 50.38 (44.39–56.36) | 0.46 | −3.26 (−12.04–5.52) |
| 2 months Meansc (CI) | 73.96 (66.93–81.00) | 74.86 (68.96–80.76) | 0.85 | −0.90 (−10.08–8.28) |
| 6 months Meansc (CI) | 75.85 (68.24–83.46) | 80.19 (73.63–86.75) | 0.40 | −4.34 (−14.39–5.72) |
| 12 months Meansc (CI) | 75.71 (68.07–83.35) | 81.57 (74.91–88.23) | 0.26 | −5.86 (−16.00–4.28) |
| Incontinence Severity Indexe Scores | ||||
| Baseline Mean (CI) | 7.14 (6.40–7.88) | 7.00 (6.25–7.75) | 0.79 | 0.14 (2.82–3.56) |
| 2 months Meansc (CI) | 4.74 (3.54–5.94) | 5.18 (4.17–6.19) | 0.58 | −0.44 (−2.01–1.12) |
| 6 months Meansc (CI) | 4.87 (3.60–6.13) | 4.69 (3.58–5.79) | 0.83 | 0.18 (−1.50–1.86) |
| 12 months Meansc (CI) | 3.64 (2.52–4.76) | 3.33 (2.34–4.31) | 0.67 | 0.32 (−1.17–1.81) |
| Patient Perception Bladder Conditionsf Scores | ||||
| Baseline Mean (CI) | 4.19 (3.90–4.47) | 4.25 (4.03–4.47) | 0.72 | −0.06 (−0.42–0.29) |
| 2 months Meansc (CI) | 3.19 (2.75–3.64) | 3.35 (2.98–3.72) | 0.59 | −0.16 (−0.74–0.42) |
| 6 months Meansc (CI) | 3.12 (2.67–3.58) | 2.71 (2.31–3.10) | 0.17 | 0.42 (−0.19–1.02) |
| 12 months Meansc (CI) | 2.93 (2.46–3.40) | 2.65 (2.24–3.06) | 0.37 | 0.29 (−0.34–0.91) |
| Prolapse & Incontinence Sexual Questionnaire-12g Scores | ||||
| Baseline Mean (CI) | 85.60 (79.57–91.62) | 86.65 (81.69–91.62) | 0.99 | 0.065 (−7.71–7.84) |
| 2 months Meansc (CI) | 93.08 (85.29–100.86) | 91.58 (84.58–98.59) | 0.77 | 1.50 (−6.48–14.64) |
| 6 months Meansc (CI) | 92.73 (84.33–101.13) | 89.00 (81.92–96.08) | 0.50 | 3.73 (−7.29–14.75) |
| 12 months Meansc (CI) | 93.74 (86.45–101.05) | 92.36 (85.84–98.89) | 0.78 | 1.39 (−8.43–11.22) |
| # Pads on 3-day diary | ||||
| Baseline Mean (CI) | 5.52 (4.06–6.98) | 4.63 (3.57–5.70) | 0.33 | 0.89 (−0.89–2.67) |
| 2 months Meansc (CI) | 3.57 (2.37–4.77) | 2.74 (1.82–3.66) | 0.28 | 0.83 (−0.67–2.33) |
| 6 months Meansc (CI) | 3.01 (1.87–4.16) | 2.63 (1.85–3.40) | 0.58 | 0.38 (−0.99–1.76) |
| 12 months Meansc (CI) | 3.46 (2.07–4.84) | 3.07 (2.13–4.01) | 0.65 | 0.39 (−1.28–2.05) |
| # Voids on 3-day diary | ||||
| Baseline Mean (CI) | 29.07 (27.06–31.08) | 29.19 (27.14–31.24) | 0.94 | −0.12 (−2.97–2.73) |
| 2 months Meansc (CI) | 26.4 (24.29–28.59) | 25.35 (23.59–27.12) | 0.44 | 1.08 (−1.67–3.85) |
| 6 months Meansc (CI) | 25.58 (23.48–27.68) | 24.28 (22.69–25.87) | 0.32 | 1.30 (−1.31–3.91) |
| 12 months Meansc (CI) | 25.74 (23.69–27.79) | 25.37 (23.71–27.02) | 0.78 | 0.37 (−2.24–2.99) |
| > 70% improvement of Urgency Urinary Incontinence | ||||
| 2 months N (%)(CI) | 60 (86%)(CI 75–93%) | 59 (82%; CI 71%–90%) | 0.65 | OR 0.76 (0.27–2.04)h |
| 6 months N (%)(CI) | 55 (82%)(CI 71–90%) | 58 (82%; CI 71%–90%) | 1.00 | OR 1.05 (0.40–2.81)h |
| 12 months N (%)(CI) | 54 (78%)(CI 67–87%) | 53 (75%; CI 63%–84% | 0.69 | OR 0.81 (0.33–1.94)h |
| Continent (No UUI on diary) | ||||
| At 2 months N (%)(CI) | 24 (34%)(CI 23–47%) | 30 (42%; CI 30–54%) | 0.39 | OR 1.4 (0.66–2.86)h |
| At 6 months N (%)(CI) | 29 (43%)(CI 31–56%) | 28 (39%; CI 28–52%) | 0.73 | OR 0.85 (0.41–1.78)h |
| At 12 months N (%)(CI) | 25 (36%)(CI 25–49%) | 30 (42%; CI 31–55%) | 0.49 | OR 1.3 (0.62–2.69)h |
| No UUI at all follow-up N (%;CI) | 11 (16%)(CI 8.–27%) | 16 (23%; CI 14–34%) | 0.39 | OR 1.5 (0.60–4.00)h |
| Treatment Compliance | ||||
| At 2 months N (%)(CI) | 67/70 (96%) | 61/72 (85%) | 0.63 | OR 1.13 (0.68–1.87)h |
| At 6 months N (%)(CI) | 54/67 (81%) | 55/71 (77%) | 0.90 | OR 1.04 (0.61–1.77)h |
| At 12 months N (%)(CI) | 53/69 (77%) | 47/71 (66%) | 0.60 | OR 1.16 (0.67–2.00)h |
Estimated group differences & 95% Confidence Intervals (CI) were derived using linear mixed models. .
Validated questionnaire reflecting symptoms. Higher scores indicate more symptoms; higher scores are worse. Score range 0–100. < 2% missing data
Adjusted Means
Validated questionnaire reflecting quality of life. Higher scores indicate better quality of life: higher scores are better. Score range 0–100. <1% missing data
Validated index. Higher scores indicate greater incontinence severity. Score range 1–12. 2% missing data
Validated global scale regarding patient’s perception of the severity of their bladder condition. Lower scores are better, Higher scores are worse. Score range=1–6. No missing data
Validated sexual function questionnaire in women with prolapse or incontinence. Higher scores are better. Range=0–123. Only administered to women having heterosexual relations in the last 6 months (33 women in each group: met criteria and answered these questions).
Odds ratios (OR) & 95% Confidence Intervals (CI) based on Fisher’s Exact test